UPDATE : Monday, February 17, 2020
상단여백
Luxturna to open gene therapies market: analyst by Nam Doo-hyun 2018-01-10 15:48
Test for fetal sex chromosome defects wins patent by Nam Doo-hyun 2018-01-10 14:39
Antibodies drug suggested against N. Korean anthrax threat by Nam Doo-hyun 2018-01-05 12:03
Venture capital investment in biomedical sector drops 20% in 2017 by Nam Doo-hyun 2018-01-04 09:30
70% of biotech firms enjoy stock price gains in 2017 by Nam Doo-hyun 2018-01-02 17:42
라인
Kolon Life Science’s shares plummet on drifting export deal by Nam Doo-hyun 2017-12-21 13:16
₩500-billion Invossa technology export to Japan in peril by Nam Doo-hyun 2017-12-20 14:59
Will Takeda, Dong-A ST benefit from new hypertension guideline? by Nam Doo-hyun 2017-12-19 16:15
Boehringer Ingelheim Korea’s labor union protests early retirement program by Nam Doo-hyun 2017-12-19 14:35
‘Celltrion’s annual revenue to top ₩3 trillion in 5 years’ by Nam Doo-hyun 2017-12-18 15:55
라인
Yuhan’s chemo combo YH24931 more effective than immunotherapy alone by Nam Doo-hyun 2017-12-18 11:51
‘Postmenopausal women in 50s shouldn’t take phytoestrogen’ by Nam Doo-hyun 2017-12-18 10:49
‘Surge of gene-therapy providing hospitals to benefit Invossa’ by Nam Doo-hyun 2017-12-12 15:59
PCL shares rise despite regulator’s warning by Nam Doo-hyun 2017-12-12 11:02
Oscotec shares rebound on launch of US clinical trial by Nam Doo-hyun 2017-12-11 15:50
라인
ToolGen’s shares jump on gene therapy market expectations by Nam Doo-hyun 2017-12-11 15:16
Government’s mobile healthcare pilot project proves effective by Nam Doo-hyun 2017-12-07 14:37
Novartis Korea faces tax investigation by Nam Doo-hyun 2017-12-06 10:55
Kolon Life Science confident to make Invossa global blockbuster by Nam Doo-hyun 2017-12-06 09:30
Shares of biotech firms, listed with ‘exceptional techs,’ rise above offer price by Nam Doo-hyun 2017-12-05 14:38
여백
여백
여백
Back to Top